A Phase 3 interventional study of Centanafadine SR and Placebo in Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-10-18.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 5th largest by enrollment, is one of 4 that started in 2019, is one of 10 in phase 3, and was the 3rd registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
By country, each count listing its studies:
centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 12
First in 2014; this study’s year is marked. 4 started in 2019.
This study's enrollment of 590 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 180 across the 20 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd.: 5 open now, 5 under way, 5 of them phase 3. Of 20 finished, 8 (40%) have results posted.
Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment, is one of 4 that started in 2019, is one of 10 in phase 3, and was the 8th registered.
Otsuka Holdings Co., Ltd.’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2010.
3 of the studies testing centanafadine in Attention Deficit Disorder with Hyperactivity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT07087327Phase 3Otsuka Pharmaceutical Co., Ltd.A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
| NCT07086313Phase 3Otsuka Pharmaceutical Co., Ltd.A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 25 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with ADHD. Participants either received a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.
Screening \& Washout Period: up to 28 days Investigational Treatment Period: 49 days Follow-up Period : 7 days or 10 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
Other: Placebo
Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
Drug: Centanafadine SR
Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
Drug: Centanafadine SR
Following Single-blind Run-in Period, participants with \<30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
Other: Placebo
100 mg, BID, oral tablets
Also known as: EB-1020
BID, oral tablet
200 mg, BID, oral tablets
Also known as: EB-1020
Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42
The AISRS is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Mixed-effect model repeated measure (MMRM) was used for the analysis.
Time frame: Baseline and Day 42
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Day 42
CGI-S is an observer-rated scale used to measure symptom severity with a total score range of 0 to 7 where 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. MMRM was used for the analysis.
Time frame: Baseline and Day 42
Adverse Event Reporting
Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine safety and tolerability of centanafadine SR tablets
Time frame: Up to 59 days
ADHD Impact Module - Adult (AIM-A)
Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.
Time frame: Up to 42 days
Adult ADHD Self Report Scale (ASRS)
An 18 question report, total score ranges from 0 to 124. A higher score denotes a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study
Time frame: Up to 42 days
AISRS
Change from baseline total score compared to every scheduled visit. Each subscale is composed of 9 items each. Scores can range from 0 to 27, with a higher score representing a worse outcome. Change from baseline scores are compared to every scheduled visit score.
Time frame: Up to 42 days
Participants took part in the study at 48 investigative sites in the United States from 16 January 2019 to 14 May 2020.
| Milestone | Single-blind Run-in Period: Placebo | Double-blind Treatment Period: Centanafadine SR 200 mg | Double-blind Treatment Period: Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|---|
| Started | 590 | 0 | 0 | 0 |
| Treated | 579 | 0 | 0 | 0 |
| Completed | 440 | 0 | 0 | 0 |
| Not completed | 150 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 4 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 4 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 0 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 5 | 0 | 0 | 0 |
| Withdrew: Physician decision | 7 | 0 | 0 | 0 |
| Withdrew: Reason not related to covid-19 | 85 | 0 | 0 | 0 |
| Withdrew: Covid-19 related | 15 | 0 | 0 | 0 |
| Withdrew: Discontinued prior to the treatment. | 1 | 0 | 0 | 0 |
| Milestone | Single-blind Run-in Period: Placebo | Double-blind Treatment Period: Centanafadine SR 200 mg | Double-blind Treatment Period: Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|---|
| Started | 0 | 147 | 147 | 146 |
| Treated | 0 | 145 | 143 | 142 |
| Completed | 0 | 111 | 102 | 123 |
| Not completed | 0 | 36 | 45 | 23 |
| Withdrew: Randomized but not treated in double-blind treatment period | 0 | 2 | 4 | 4 |
| Withdrew: Adverse event | 0 | 5 | 8 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 5 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 4 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 5 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 10 | 6 | 4 |
| Withdrew: Physician decision | 0 | 3 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 6 | 16 | 7 |
| Withdrew: Covid-19 related | 0 | 0 | 2 | 1 |
The AISRS is an 18-item clinician rating scale to evaluate individual ADHD symptoms on a scale of 0 (none) to 3 (severe). The total sum ranges from 0 (no ADHD symptoms) to 54 (extremely severe ADHD symptoms). Mixed-effect model repeated measure (MMRM) was used for the analysis.
| score on a scale | Double-blind Treatment Period: Centanafadine SR 200 mg | Double-blind Treatment Period: Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Change From Baseline in ADHD Investigator Symptom Rating Scale (AISRS) Score at Day 42 | -12.1 ± 0.96 | -12.5 ± 0.99 | -8.07 ± 0.94 |
CGI-S is an observer-rated scale used to measure symptom severity with a total score range of 0 to 7 where 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A negative change from Baseline indicates improvement. MMRM was used for the analysis.
| score on a scale | Double-blind Treatment Period: Centanafadine SR 200 mg | Double-blind Treatment Period: Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo |
|---|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Day 42 | -1.04 ± 0.09 | -0.99 ± 0.09 | -0.71 ± 0.09 |
Frequency and severity of treatment-emergent adverse events (TEAEs) will be assessed to determine safety and tolerability of centanafadine SR tablets
Results for this outcome have not been posted.
Scale composed of 3 subscales with a maximum score of 100. A lower score indicates a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study.
Results for this outcome have not been posted.
An 18 question report, total score ranges from 0 to 124. A higher score denotes a worse outcome. Exploratory endpoint; comparison of baseline score to other points throughout the study
Results for this outcome have not been posted.
Change from baseline total score compared to every scheduled visit. Each subscale is composed of 9 items each. Scores can range from 0 to 27, with a higher score representing a worse outcome. Change from baseline scores are compared to every scheduled visit score.
Results for this outcome have not been posted.
Collected over Up to 59 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: Single-blind Run-in Period Only | 0/149 (0%) | 0/149 (0%) | 9/149 (6%) |
| Placebo + Centanafadine SR 200 mg | 0/145 (0%) | 1/145 (0.7%) | 31/145 (21.4%) |
| Placebo + Centanafadine SR 400 mg | 0/143 (0%) | 0/143 (0%) | 47/143 (32.9%) |
| Placebo + Placebo | 0/142 (0%) | 0/142 (0%) | 24/142 (16.9%) |
| Event | Placebo: Single-blind Run-in Period Only | Placebo + Centanafadine SR 200 mg | Placebo + Centanafadine SR 400 mg | Placebo + Placebo |
|---|---|---|---|---|
| BronchitisInfections and infestations | 0/149 | 1/145 | 0/143 | 0/142 |
| Event | Placebo: Single-blind Run-in Period Only | Placebo + Centanafadine SR 200 mg | Placebo + Centanafadine SR 400 mg | Placebo + Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/149 | 5/145 | 15/143 | 3/142 |
| HeadacheNervous system disorders | 5/149 | 11/145 | 15/143 | 8/142 |
| Decreased ApettiteMetabolism and nutrition disorders | 1/149 | 6/145 | 10/143 | 3/142 |
| Dry MouthGastrointestinal disorders | 1/149 | 3/145 | 9/143 | 1/142 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/149 | 9/145 | 5/143 | 5/142 |
| DiarrhoeaGastrointestinal disorders | 0/149 | 4/145 | 8/143 | 3/142 |
| InsomniaPsychiatric disorders | 1/149 | 3/145 | 8/143 | 3/142 |
Participants who participated only in the Run-in Period and Full Analysis Set (FAS) of the Double-blind Treatment Period including all participants of the safety sample of Double-blind Treatment Period who had a Baseline value and at least one valid post-randomization efficacy evaluation for adult ADHD investigator symptom rating scale (AISRS) total score in the Double-blind Treatment Period.
| Age, Continuous(years) | Placebo: Single-blind Run-in Period Only | Double-blind Treatment Period: Placebo + Centanafadine SR 200 mg | Double-blind Treatment Period: Placebo + Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo + Placebo | Total |
|---|---|---|---|---|---|
| Mean | 33.7 ± 9.6 | 34.5 ± 9.7 | 35.2 ± 10.4 | 35.2 ± 9.6 | 34.6 ± 9.8 |
| Sex: Female, Male(Participants) | Placebo: Single-blind Run-in Period Only | Double-blind Treatment Period: Placebo + Centanafadine SR 200 mg | Double-blind Treatment Period: Placebo + Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo + Placebo | Total |
|---|---|---|---|---|---|
| Female | 70 | 71 | 70 | 66 | 277 |
| Male | 80 | 76 | 77 | 80 | 313 |
| Ethnicity (NIH/OMB)(Participants) | Placebo: Single-blind Run-in Period Only | Double-blind Treatment Period: Placebo + Centanafadine SR 200 mg | Double-blind Treatment Period: Placebo + Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo + Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 30 | 27 | 23 | 29 | 109 |
| Not Hispanic or Latino | 119 | 117 | 122 | 116 | 474 |
| Unknown or Not Reported | 1 | 3 | 2 | 1 | 7 |
| Race (NIH/OMB)(Participants) | Placebo: Single-blind Run-in Period Only | Double-blind Treatment Period: Placebo + Centanafadine SR 200 mg | Double-blind Treatment Period: Placebo + Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo + Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 2 | 4 |
| Asian | 4 | 10 | 2 | 6 | 22 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 0 | 2 |
| Black or African American | 26 | 17 | 19 | 21 | 83 |
| White | 116 | 112 | 120 | 114 | 462 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 7 | 4 | 3 | 17 |
| Adult Attention-deficit/Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale(AISRS) Score(score on a scale) | Placebo: Single-blind Run-in Period Only | Double-blind Treatment Period: Placebo + Centanafadine SR 200 mg | Double-blind Treatment Period: Placebo + Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo + Placebo | Total |
|---|---|---|---|---|---|
| Mean | — | 37.6 ± 6.7 | 38.6 ± 7.0 | 37.8 ± 6.5 | 38.0 ± 6.7 |
| Clinical Global Impression-Severity of Illness Scale (CGI-S) Score(score on a scale) | Placebo: Single-blind Run-in Period Only | Double-blind Treatment Period: Placebo + Centanafadine SR 200 mg | Double-blind Treatment Period: Placebo + Centanafadine SR 400 mg | Double-blind Treatment Period: Placebo + Placebo | Total |
|---|---|---|---|---|---|
| Mean | — | 4.6 ± 0.6 | 4.6 ± 0.5 | 4.5 ± 0.6 | 4.6 ± 0.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jan 2019 to primary completion in May 2020, 15 months.
Results were first posted in Oct 2021, 1 year 5 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 15 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Centanafadine
Attention Deficit Disorder with Hyperactivity →
Otsuka Pharmaceutical Development & Commercialization, Inc. →